News
ASLN
--
0.00%
--
Implied Volatility Surging for ASLAN Pharmaceuticals (ASLN) Stock Options
Investors need to pay close attention to ASLAN Pharmaceuticals (ASLN) stock based on the movements in the options market lately.
Zacks · 6d ago
ASLAN Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference
MENLO PARK, Calif. and SINGAPORE, Sept. 09, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr ...
GlobeNewswire · 09/09 11:00
ASLAN Pharmaceuticals EPS misses by $0.02
ASLAN Pharmaceuticals (NASDAQ:ASLN): Q2 GAAP EPS of -$0.10 misses by $0.02. Cash and cash equivalents totalled $94.1M. Press Release
Seekingalpha · 08/06 11:27
BRIEF-Aslan Pharmaceuticals Posts Qtrly Loss Per Ordinary Share $0.02
reuters.com · 08/06 11:17
ASLAN Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Recruitment completed in June for the expansion cohort of the Multiple Ascending Dose (MAD) trial of ASLAN004, underway for the treatment of patients with moderate-to-severe atopic dermatitis Topline, unblinded data from approximately 27 additional patient...
GlobeNewswire · 08/06 11:00
ASLAN Pharmaceuticals to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference
SINGAPORE, Aug. 04, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, will pa...
GlobeNewswire · 08/04 11:00
Were Hedge Funds Right About ASLAN Pharmaceuticals Limited (ASLN)?
Is ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduat...
Insider Monkey · 07/28 02:38
3 Biotech Stocks Wall Street Predicts Will Rally by More Than 170%
StockNews.com · 07/22 10:22
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers
Benzinga · 07/19 21:30
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers
Benzinga · 07/15 20:34
Clene, Inhibikase Therapeutics leads healthcare gainers; IMV, Tempest Therapeutics among major losers
Gainers: Clene (CLNN) +8%, Inhibikase Therapeutics (IKT) +7%, ASLAN Pharmaceuticals (ASLN) +5%, Doximity (DOCS) +5%.Losers: IMV (IMV) -26%, Tempest Therapeutics (TPST) -25%, Sonoma Pharmaceuticals (SNOA) -23%, Immunic (IMUX) -18%, Virpax Pharmaceuticals (V...
Seekingalpha · 07/15 15:02
ASLAN Pharmaceuticals Draws Down Full $20 Million Tranche to Advance Autoimmune Gastrointestinal Disease Treatment
MT Newswires · 07/14 06:53
The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 12)
Benzinga · 07/13 12:05
ASLAN Pharma Secures Debt Funding Of $45M To Support ASLAN003 Development
Benzinga · 07/13 12:03
ASLAN Pharmaceuticals Announces Loan Facility Providing Up to $45 Million From K2 HealthVentures
Funds extend expected cash runway through late 2023 and enable advancement of clinical program for ASLAN003SINGAPORE, July 13, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company devel...
GlobeNewswire · 07/13 11:00
12 Health Care Stocks Moving In Monday's Intraday Session
 
Benzinga · 07/12 16:41
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Delcath Systems (NASDAQ:DCTH) stock increased by 8.87% to $11.9 during Friday's after-market session. This security traded at a volume of 379 shares come close, making up 0.45% of its average volume over the last 100 days. The company's market cap...
Benzinga · 07/09 21:20
Galectin Therapeutics, ReShape Lifesciences leads healthcare gainers; Sigilon Therapeutics, Aerpio Pharmaceuticals among major losers
Gainers: Galectin Therapeutics GALT +40%, ReShape Lifesciences (RSLS) +21%, INmune Bio (INMB) +17%, ASLAN Pharmaceuticals (ASLN) +15%, 89bio (ETNB) +14%.Losers: Sigilon Therapeutics SGTX -30%, Aerpio Pharmaceuticals (ARPO) -14%, Alterity Therapeutics (ATHE...
Seekingalpha · 07/09 14:56
Benzinga's Top Ratings Upgrades, Downgrades For July 9, 2021
h2>Upgrades
Benzinga · 07/09 14:36
Thinking about buying stock in Galectin Therapeutics, Hall of Fame Resort & Entertainment, PubMatic, 360 DigiTech, or Aslan Pharmaceuticals?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GALT, HOFV, PUBM, QFIN, and ASLN.
PR Newswire - PRF · 07/09 13:31
Webull provides a variety of real-time ASLN stock news. You can receive the latest news about Aslan Pharms through multiple platforms. This information may help you make smarter investment decisions.
About ASLN
ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The Company is engaged in developing treatments to transform the lives of patients. The Company is developing ASLAN004, an antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, an oral inhibitor of dihydroorotate dehydrogenase (DHODH), which is being developed for autoimmune disease. The Company's ASLAN004 is a fully human monoclonal antibody targeting the IL-13 receptor a1 subunit (IL-13Ra1). By targeting IL-13Ra1, which forms the Type II receptor complex with IL-4Ra, ASLAN004 inhibits signaling of both interleukin 4 (IL-4) and interleukin 13 (IL-13). IL-4 and IL-13 are central to triggering symptoms of allergy in atopic dermatitis, such as redness and itching of the skin, as well as asthma symptoms such as shortness of breath, wheeze and cough.